523 related articles for article (PubMed ID: 30778015)
1. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
[TBL] [Abstract][Full Text] [Related]
2. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
3. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
4. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
[TBL] [Abstract][Full Text] [Related]
5. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
6. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
Chinder PS; Hindiskere S; Doddarangappa S; Pal U
Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
[TBL] [Abstract][Full Text] [Related]
9. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities.
Campanacci L; Sambri A; Medellin MR; Cimatti P; Errani C; Donati DM
Acta Orthop Traumatol Turc; 2019 Sep; 53(5):376-380. PubMed ID: 31253385
[TBL] [Abstract][Full Text] [Related]
10. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
Asano N; Saito M; Kobayashi E; Morii T; Kikuta K; Watanabe I; Anazawa U; Takeuchi K; Suzuki Y; Susa M; Nishimoto K; Ishii R; Miyazaki N; Mrioka H; Kawai A; Horiuchi K; Nakayama R
Ann Surg Oncol; 2022 Jun; 29(6):3992-4000. PubMed ID: 35175454
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.
Puri A; Gulia A; Hegde P; Verma V; Rekhi B
Bone Joint J; 2019 Feb; 101-B(2):170-177. PubMed ID: 30700112
[TBL] [Abstract][Full Text] [Related]
13. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
[TBL] [Abstract][Full Text] [Related]
14. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A
Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
17. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
18. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C
Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
[TBL] [Abstract][Full Text] [Related]
19. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
[TBL] [Abstract][Full Text] [Related]
20. Is Navigation-guided En Bloc Resection Advantageous Compared With Intralesional Curettage for Locally Aggressive Bone Tumors?
Farfalli GL; Albergo JI; Piuzzi NS; Ayerza MA; Muscolo DL; Ritacco LE; Aponte-Tinao LA
Clin Orthop Relat Res; 2018 Mar; 476(3):511-517. PubMed ID: 29529633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
